Loading...

Home
ETF
RAPP

RAPP

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

RAPP News

Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials

Jan 08 2026NASDAQ.COM

Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million

Dec 22 2025Fool

Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $61.38 Million

Dec 22 2025NASDAQ.COM

Rapport Therapeutics, Inc. (RAPP) Sees a 9.03% Increase Over the Past Week: Key Insights to Consider

Dec 08 2025NASDAQ.COM

Valuation Assessment of Rapport Therapeutics (RAPP) Following 60% Increase in Share Price This Year

Dec 07 2025Yahoo Finance

RAP-219 Phase 2a Seizure Results and Upcoming Pivotal Trials Could Influence Investment Decisions in Rapport Therapeutics (RAPP)

Dec 06 2025Yahoo Finance

Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency

Dec 05 2025Globenewswire

Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency

Dec 05 2025Newsfilter

Extreme Networks Analyst Starts Coverage with Optimism; Check Out the Top 5 Initiations for Wednesday

Nov 19 2025Benzinga

Biotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.

Nov 03 2025MarketWatch

Biotech Stocks Surge in After-Hours Trading on Friday in Anticipation of Important Clinical Trial Announcements

Sep 22 2025NASDAQ.COM

Rapport Therapeutics, Inc. (RAPP) Shares Insights at TD Cowen's 5th Annual Summit on Novel Mechanisms in Neuropsychiatry and Epilepsy

Sep 17 2025Newsfilter

Insider Buying Update for Wednesday, September 17: LBRX and RAPP

Sep 17 2025NASDAQ.COM

Truist Securities Begins Coverage of Rapport Therapeutics (RAPP) with a Buy Rating

Sep 17 2025NASDAQ.COM

Truist Securities Begins Coverage of Rapport Therapeutics with a Buy Rating and Sets Price Target at $44

Sep 16 2025Benzinga

Top Analysts Recommend 3 Stocks to Purchase Now, 9/16/2025

Sep 16 2025TipRanks